Cargando…

Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis

INTRODUCTION: For people with type 2 diabetes (T2DM) inadequately controlled with oral antidiabetic drugs (OADs), evidence from both randomized controlled trials (RCTs) and real-world studies has demonstrated that treatment intensification with liraglutide offers effective glycemic control, weight r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorenzi, Maria, Ploug, Uffe Jon, Langer, Jakob, Skovgaard, Rasmus, Zoratti, Michael, Jansen, Jeroen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306116/ https://www.ncbi.nlm.nih.gov/pubmed/27995594 http://dx.doi.org/10.1007/s13300-016-0217-4

Ejemplares similares

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
por: Chua, Marvin Wei Jie
Publicado: (2021)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
por: Li, Qian, et al.
Publicado: (2014)

Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013)

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden
por: Lind, Marcus, et al.
Publicado: (2016)

Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study
por: Ghosal, S., et al.
Publicado: (2018)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i
por: Blonde, Lawrence, et al.
Publicado: (2021)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Neuroprotective Effect of SGLT2 Inhibitors
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
por: Lin, Chu, et al.
Publicado: (2021)

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide
por: DeKoven, Mitch, et al.
Publicado: (2014)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
por: Cho, Hyun A, et al.
Publicado: (2017)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England
por: Gough, Stephen CL, et al.
Publicado: (2009)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis
por: Masson, Walter, et al.
Publicado: (2021)

Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysis
por: Lin, Chu, et al.
Publicado: (2021)

Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
por: Chen, Jui-Yi, et al.
Publicado: (2023)

The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
por: Elhini, Sahar H., et al.
Publicado: (2022)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Recommendations on the Proper Use of SGLT2 Inhibitors
Publicado: (2019)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
por: Szekeres, Zsolt, et al.
Publicado: (2021)

SGLT2 Inhibitors: the Gift that Keeps on Giving
por: Garcia, Maria Victoria Faith, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

Euglycemic DKA Associated With SGLT2 Inhibitors
por: TakallooBakhtiari, Asieh, et al.
Publicado: (2021)

The Role of SGLT2 Inhibitors in Vascular Aging
por: Liu, Le, et al.
Publicado: (2021)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

Direct cardiac effects of SGLT2 inhibitors
por: Chen, Sha, et al.
Publicado: (2022)

Possible renoprotective mechanisms of SGLT2 inhibitors
por: Nishiyama, Akira, et al.
Publicado: (2023)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

SGLT2 Inhibitors as Potential Anticancer Agents
por: Basak, Debasish, et al.
Publicado: (2023)

The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
por: Ehlers, Lars Holger, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lbvi14eqncgms9bsp0orcojet9